Most patients received bisphosphonates (or an anti-RANK-L antibody) as part of their therapies due to bone metastasis (Table 1), but no correlations were observed between marker levels and bisphosphonate (or anti-RANK-L) treatment (Supplementary Figures 5 and 6), except a transient increased mobilization of CEP at day 8 of therapy with paclitaxel and bevacizumab. Here, TNFSF11 is linked to bone metastasis.